Additionally, molecular markers including DRD2 gene variants, altered expression levels of PRDM2, Filamin A, or PRB3, and dysregulated TGF-β1/Smad3 signaling pathways offer insights into the molecular pathogenesis of aggressive prolactinomas [1, 3, 4]. The gene discussed is PRB3; the disease is prolactin-producing pituitary gland adenoma.